Insulin Analog, Lispro Mixed Shortage Update: What Patients Need to Know in 2026

Humalog Mix 75/25 and Humalog Mix 50/50 — the brand-name forms of Insulin Analog, Lispro Mixed — have faced persistent availability challenges at pharmacies across the United States. This page provides the most current information on what is happening, why, and what patients should do to protect their access to this critical medication.

Is Insulin Lispro Mixed Currently in Shortage in 2026?

As of 2026, Insulin Analog, Lispro Mixed is not listed as an active national shortage on the FDA Drug Shortages database. However, patients across the country are still experiencing localized stockouts — situations where individual pharmacies, or pharmacies in a specific region, do not have the medication available even though the national supply is technically adequate.

This distinction matters: the FDA shortage database reflects systemic manufacturing failures, not store-level inventory problems. Many patients experiencing real difficulty finding their medication won't see their situation reflected in official reports.

What Happened in 2024 That Started This?

In early 2024, Eli Lilly discontinued Humalog 3 mL vials — a popular format for patients who used smaller doses or preferred a compact size. While Lilly cited "the dynamic nature of insulin supply and demand, coupled with brief delays in manufacturing," patients who relied on those smaller vials were left scrambling. The 10 mL vials and KwikPen versions continued to be manufactured and have largely returned to availability, but some pharmacies that relied on the 3 mL format took months to transition.

Even after supply stabilized nationally, uneven distribution created pockets of unavailability. Smaller rural pharmacies, pharmacies with low insulin demand, and pharmacies that had depleted buffer stock during the disruption were the hardest hit.

What Is the Current Supply Situation in 2026?

The national supply of Humalog Mix products has largely stabilized as of 2026. Eli Lilly continues to manufacture Humalog Mix 75/25 and Mix 50/50 in 10 mL vials and KwikPens. However, the mixed formulations have limited generic competition compared to plain insulin lispro, which means fewer backup supply sources exist when demand spikes or a shipment is delayed.

Spot shortages persist at the local level. Patients in rural areas, smaller cities, or regions with higher insulin demand relative to supply may still experience difficulty finding stock on any given day. The problem is not a shortage in the traditional sense — it is distribution and pharmacy ordering variability.

How Is This Different From a Traditional Drug Shortage?

A traditional drug shortage occurs when a manufacturer cannot produce enough of a medication to meet demand — due to raw material problems, facility closures, regulatory issues, or product discontinuation. What patients with Insulin Analog, Lispro Mixed are experiencing is more accurately described as a distribution access problem: the medication exists, but getting it to the right pharmacy at the right time is inconsistent.

This type of access issue is harder for health authorities to track and report because it does not show up in manufacturer production numbers. For patients, it can feel exactly like a shortage — because at your pharmacy, it is.

What Should Patients Do Right Now?

Here are immediate steps to protect your access to Insulin Analog, Lispro Mixed:

• Refill early. Do not wait until you are completely out. Most insurance plans allow refills when 7–10 days of supply remain. Refill as soon as you are eligible.
• Use medfinder. medfinder calls pharmacies near you to check which ones have your medication in stock, then texts you the results. This is the fastest way to find it without calling pharmacies yourself.
• Consider mail order. Mail-order pharmacies typically maintain better stock levels than retail and often offer 90-day supplies at reduced copays.
• Talk to your prescriber proactively. Ask your doctor whether a backup plan or alternative insulin is appropriate given the access situation in your area. Having a contingency prescription ready is better than scrambling in an emergency.

Has the Price of Insulin Lispro Mixed Changed in 2026?

Yes — and the news is largely good. Eli Lilly's Insulin Value Program caps monthly insulin costs at $35 for patients with commercial insurance or those paying cash. For Medicare patients, the Inflation Reduction Act caps out-of-pocket insulin costs at $35 per month per product under Part D.

The cash retail price for Humalog Mix 75/25 without insurance is still significant — approximately $150–$280 for a 10 mL vial — but with the Lilly program or a GoodRx coupon (as low as $81.36), the cost burden has decreased substantially from its peak.

What Is Lilly Doing to Address Availability?

Eli Lilly has publicly acknowledged past supply disruptions and has stated that manufacturing has returned to normal. The company continues to produce Humalog Mix products in 10 mL vials and KwikPens. However, because the mixed formulation is a more specialized product than plain insulin lispro, it may be prioritized differently in Lilly's production and distribution schedule.

For more on how to locate this medication, see: How to Find Insulin Analog, Lispro Mixed in Stock Near You.